Spotlight on New PrEP Tools and Data

From R&D to Access

28 November 2023
Welcome!

**PrEP Watch**

Explore data and information on PrEP across the globe.

**LAPaL**

The long-acting therapeutics patents and licences database.

**Access to Medicines Tracker**
<table>
<thead>
<tr>
<th>Agenda</th>
<th></th>
</tr>
</thead>
</table>
| **Welcome**       | Mitchell Warren, AVAC  
                    | Cherise Scott, Unitaid |
| **The Current PrEP Landscape** | Catherine Verde Hashim, AVAC  
                                     | Sébastien Morin, MPP |
| **PrEPWatch**     | Janki Tailor, AVAC  
                    | Catherine Verde Hashim, AVAC |
| **The Long-Acting Therapeutics Patents and Licenses Database** | Lobna Gaayeb, MPP |
| **Access to Medicines Tracker** | Sébastien Morin, MPP |
| **When do I use each tool?** | Janki Tailor and Catherine Verde Hashim, AVAC  
                                    | Lobna Gaayeb, MPP |
| **Interactive Quiz** | Wawira Nyagah, AVAC  
                            | Lobna Gaayeb, MPP |
| **Q&A**           | Anne-Isabelle Cameron, Unitaid |
The Current PrEP Landscape
The PrEP Landscape - Initiations

5.7m initiations to Sept 2023
Access to generic CAB-LA for PrEP: Update on licensing and outlook for broad access

Webinar – Spotlight on new PrEP tools and data: From R&D to access
Convened by AVAC, MPP, and Unitaid on 28 November 2023
Presented by Sébastien Morin (Medicines Patent Pool)
**Overview of the voluntary licensing model**

- Driving prices down through generic competition
- Accelerating timelines for generic product availability

**Graph**

- Originator price (in absence of generic competition)
- Prices with generic competition

**Generic competition induced pricing benchmarks**: Dave et al. (2017) *NEJM*

More at: [https://medicinespatentpool.org](https://medicinespatentpool.org)
Access to MPP-licensed medicines

Patent and licence information tools

- To support procurement agencies, national programmes, and treatment advocates
- Fully public quarterly-updated country-by-country information

More at: https://medicinespatentpool.org/what-we-do/medspal
https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker
MPP strategy for 2023-2025

Greater access to medicines and health technologies for those who need them, 2023
https://medicinespatentpool.org/what-we-do/strategy

Peer-reviewed publications

The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study
https://doi.org/10.1016/S2667-2468(22)26672-5

Journal of the International AIDS Society, 2023
https://doi.org/10.1002/jia2.26092
https://www.youtube.com/watch?v=h57gXs4aQtg

Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
https://doi.org/10.1136/bmjgh-2023-012964

BMJ Global Health, 2023
http://dx.doi.org/10.1136/bmjgh-2023-012964
CAB-LA as one more HIV prevention option

“CAB-LA should be delivered as an additional choice alongside other PrEP options, including oral PrEP and the DVR, as part of a comprehensive HIV prevention approach.”

CAB-LA for PrEP is
- Recommended by WHO
- Approved in several countries
- Effective, well tolerated, safe
- Taken as an injection every 2 months
- Patented until 2031 but licensed to MPP – thanks in large parts to community advocacy efforts!

More at: https://medicinespatentpool.org/licence-post/cabotegravir-long-acting-la-for-hiv-pre-exposure-prophylaxis-prep
https://www.who.int/publications/i/item/9789240054097

Prevention

- Oral PrEP (TDF/XTC)  
  Patents expired
- CAB-LA  
  MPP licence
- Dapivirine vaginal ring  
  Population Council

MPP-ViiV licence for CAB-LA for PrEP

The licence covers the patents on CAB-LA for PrEP, enabling the development and supply of generic versions.

The market for CAB-LA for PrEP is uncertain and investments from generic manufacturers might be significant; hence the decision to have a maximum of three licensees (this could be revised at a later stage).

Technical and financial support to manufacturers is being explored, such as technology transfer from ViiV to licensees.

Development and approval of generic versions will likely take 3-4 years from now; meanwhile, the only source of CAB-LA will be the originator product from ViiV Healthcare.

+ Quality: WHO PQ or SRA approval required

+ Transparency: the licence is published in full on the MPP website

More at: https://medicinespatentpool.org/licence-post/cabotegravir-long-acting-la-for-hiv-pre-exposure-prophylaxis-prep
Partnering with generics

Sub-licensee selection process

- MPP invites qualified product developers to apply for licences to manufacture and sell licensed medicines in LMICs; this is done through an Expression of Interest (EOI) process.
- The assessment is rigorous and objective (with blinded review for short-listing), and responses are graded using a standardised tool and top-scoring applicants are selected.
- The number of licences granted is informed by demand forecasts and other information.

By granting multiple sublicences, MPP aims to support adequate supply and competitive pricing

For CAB-LA, there was also an onsite audit of short-listed candidate’s manufacturing plant.

Sub-licensee selection criteria

- **Capacity, capabilities and track-record** for manufacturing quality-assured medicines (including experience developing, manufacturing and/or marketing other products).
- **R&D, financials, and regulatory compliance** (including around required quality standards).
- **Specific plans** for the licensed product (regarding development, manufacturing, regulatory plan, distribution, and projected investments – viability of those plans, especially in case of projects requiring specific capital expenditure or investments).
- **Readiness with needed formulation technologies** (e.g., FDCs, paediatrics).
- **Past experience and performance as MPP licensee**.

More at: https://medicinespatentpool.org/partners/how-to-get-or-give-a-licence
MPP licence for CAB-LA for PrEP
– Understanding the effective territory

The effective licence territory covers: all countries listed + countries without patents and where supply may be possible

Countries listed (90)
• All low-income countries
• All lower middle-income countries
• All sub-Saharan African countries
• All least-developed countries

Countries without patents and where supply may be possible
• Based on data from MedsPaL (www.medspal.org)

Source: Beatriz Grinsztejn, Long-acting PrEP implementation: Fostering access and equity, AIDS 2022

More at: https://medicinespatentpool.org/licence-post/cabotegravir-long-acting-la-for-hiv-pre-exposure-prophylaxis-prep
https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker
MPP licence for CAB-LA for PrEP – Navigating the effective territory

MPP’s interactive map focuses on low- and middle-income countries. Access in high-income countries is generally not included.

More at: https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker

Closing message & ideas for future increased collaboration

Now is the time to (1) continue expanding access to oral PrEP and (2) plan for the introduction of CAB-LA for PrEP in anticipation of future availability of generic versions!

We can share information about access to MPP-licensed medicines in your region or country and support you in many ways

• Please tell us about your needs to increase generic competition for a given product
• Please notify us of stock-outs, quality issues, registration delays, or other challenges regarding MPP-licensed medicines

Do not hesitate to be in touch!

Sébastien Morin, PhD
Policy and Advocacy Manager
Medicines Patent Pool
Geneva, Switzerland

smorin@mppf.ch
Thanks for your attention!

I will be happy to continue the discussion, including over emails (smorin@mppf.ch)
Introducing PrEPWatch
Introducing PrEPWatch

Country Data Resources

Global PrEP Tracker

Explore the Data

This tool contains a database with detailed information on the status of PrEP approval and delivery to patients and communities.

Explore Publications

A library of publications and presentations featuring data from the PrEP Tracker.

Global PrEP Tracker & Country Pages

Raw Data
Introducing PrEPWatch

The Resource Library- 770+ Resources and Growing

- Tools for advocates
- Demand generation resources
- Costing guides
- M&E tools
- WHO guidelines
- National HIV strategies
- Published research
- Service delivery best practice
- …and more

Filter by topic, product, format, population, region, country, and/or language
Introducing PrEPWatch

Delivering PrEP- Highlights from the Resource Library

- The most important and widely-used resources, organised by stage of the rollout process
- Product-specific rollout toolkits:
  - Plan 4 Oral PrEP
  - Plan 4 Ring
Introducing PrEPWatch

Dashboards

Integrated Study Dashboard for New PrEP Options

This dashboard, produced under the PrEPWatch project, reflects all currently known activities relating to implementation research, modeling, clinical research, and landscaping for new late-stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using the dashboard, please contact Catherine Locke, Studies.

Click the buttons below to navigate to the dashboards, organized by study type, or click “Add Study Details” for a table of all studies. You can also navigate through the dashboards using the arrows at the bottom of the screen. The graphs below summarize all studies by location, product, and study type.

All graphs are interactive, and clicking on a graph element will filter all other graphs on the page accordingly. To clear a filter, either click on the graph element again, or click the “Clear filters” button. For additional details on any of the studies, right-click on the relevant graph element and select “Drill through to Study Details.” For example, right-click on South Africa on the map to get details of all studies taking place in South Africa. To expand any graph to full screen, hover over the top right corner and click “Focus mode.”

Implementation Studies

Modelling Studies

Clinical Research

Landscaping and Values

Preferences

Full Study Details

Studies by Country

Studies by Product

Studies by Type

Darker shades indicate a greater number of studies

Clear Filters

Integrated Study Tracker

Product Introduction Matrix

AVAC's County Planning for Product Introduction Matrix tracks the regulatory status of cabotegravir for PrEP and the dapivirine vaginal ring, along with related late-stage clinical trials and implementation research procurement plans and real-world progress. Use the buttons on the left to filter by region. Right-click on any number in the implementation Studies columns and select “Drill through to Study Details” for full study details. Note that “N/A” indicates year of first PrEP approval not available.

Click here to visit the PrEPWatch for full PrEP initiation data and click here to visit the study dashboard for full late-stage PrEP research data.
The PrEPWatch Team
Please do be in touch with any questions at prepwatch@avac.org or

Catherine Verde Hashim
catherine@avac.org

Janki Tailor
janki@avac.org
THE LONG-ACTING THERAPEUTICS PATENTS AND LICENCES DATABASE

A collaborative tool to support access to innovative long-acting therapeutics

LAPaL is a free online resource that provides innovation and access support on technical features, development status and intellectual property status of selected long-acting therapeutics that could have impact in low- and middle-income countries.

www.lapal.ch
WHAT ARE LAPaL’S MAIN COMPONENTS?
Long-acting technologies and compounds

INNOVATIONS for potential impact in Global Health

THE LONG-ACTING THERAPEUTICS ONE-STOP-SHOP
Long-acting therapeutics development landscape with technologies, compounds and their co-formulations

- Visualisation dashboard:
  - Insights on clinical trials
  - Overview of regulatory status

- Intellectual property landscape

- Access commitments for pipeline acceleration

INTELLECTUAL PROPERTY LANDSCAPE

DEVELOPMENT LANDSCAPE overview on clinical and regulatory aspects
Drug Combination Nanoparticles (DcNP)

Active Pharmaceutical Ingredient
- Tenofovir disoproxil fumarate (TDF)
- Lamivudine (3TC)
- Dolasetravir (DTG)
- Lopinavir and ritonavir (LPV/r)
- Tenofovir (TFV)

Route(s) of administration
- Subcutaneous

Type of technology
- Based on other organic particles
- Aqueous drug particle suspension

Other features of the technology
- Biodegradable
- Non-removable
- Room temperature storage, At least 1 year shelf life

Development stage
- Pre-clinical

Therapeutic area(s)
- HIV

Ease of administration
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- Self-administered

Drug Combination Nanoparticles (DcNP)
Targeted & Long-acting drug Combination (TLC)
Program, University of Washington

Access principles

Summary
Drug Combination Nanoparticles (DcNP)

Active Pharmaceutical Ingredient:
- Tenofovir disoproxil fumarate (TDF),
- Lamivudine (3TC), Dolutegravir (DTG),
- Lopinavir and ritonavir (LPV/r),
- Tenofovir (TFV)

Route(s) of administration:
- Subcutaneous

Type of technology:
- Based on other organic particles, aqueous drug particle suspension

Other features of the technology:
- Biodegradable, Non-removable, Room temperature storage, At least 1 year shelf life

Development stage:
- Pre-clinical

Therapeutic area(s):
- HIV

Ease of administration:
- Administered by a community health worker, Administered by a nurse, Administered by a specialty health worker, Self-administered

Access principles:

Drug Combination Nanoparticles (DcNP)

Targeted & Long-acting drug Combination (TLC)
Program, University of Washington
Drug Combination Nanoparticles (DcNP)

Therapeutic area(s)
- HIV

Use case(s)
- Treatment

Potential associated API(s)
- Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Dolutegravir (DTG)
- Lopinavir and ritonavir (LP/RT), Tenofovir (TFV)

Use of technology
- Ease of administration
  - Administered by a community health worker
  - Administered by a nurse
  - Administered by a specialist health worker
  - Self-administered

- User acceptance
  - Potentially good

Targeted user groups
- Genders
  - Male
  - Female
  - Cisgender female
  - Cisgender male
  - Transgender female
  - Transgender male
  - Intersex
  - Gender non-binary
  - All

- Age Cohort
  - Adults

- Pregnant individuals
  - Yes

- Healthy individuals
  - No

- Lactating individuals
  - Yes

- Comment
  - Not provided

Class(es)
- Antiviral

Foresseen user group
- People living with HIV (Chronic HIV positive patients)

Class(es)
- Antiviral

Foresseen user group
- People living with HIV
<table>
<thead>
<tr>
<th>Name</th>
<th>Identifier</th>
<th>Phase</th>
<th>Status</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>First in Human Clinical Trial of a Next Generation, Long-acting Injectable, Combination Antiretroviral Therapy Platform TLC-ART 101 (ACTU 2001)</td>
<td>NCT05850728</td>
<td>Phase I</td>
<td>Recruiting</td>
<td>Safety, tolerability and PK of single subcutaneous injection of TLC-ART 101 in healthy adults</td>
</tr>
</tbody>
</table>
**Clinical trial general information**

**Name**
First in Human Clinical Trial of a Next Generation, Long-acting Injectable, Combination Antiretroviral Therapy Platform TLC-ART 101 (ACTU 2001)

**Link**
https://clinicaltrials.gov/study/NCT05850728?intr=TLC-ART&rank=1

**Sponsor**
NIH

**Purpose**
Safety, tolerability and PK of single subcutaneous injection of TLC-ART 101 in healthy adults

**Countries**
United States

**Sites / Institutions**
- Seattle, Washington

**Identifier**
NCT05850728

**Phase**
Phase I

**Status**
Recruiting

**More details**
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation, de-escalation, and study duration. The study is designed to learn whether the formulation can be used as a platform for other drugs for treatment of HIV. The formulation is a drug combination nanoparticle (DCNP). The study will be conducted by UW Positive Research. The sample size for this study is 12-16. The study population consists of healthy adults without HIV. The study duration is 57 days per participant at the start of the study.

**Interventions**
- TLC-ART 101 containing lopinavir 15.6mg, ritonavir 4.2 mg, and tenofovir 9.15 mg in a combination nanoparticle suspension of 1.5 mL
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Combination Nanoparticles for multiple drugs extended release</td>
<td>WO2016205384</td>
<td>Long-acting platform</td>
<td>The University Of Washington</td>
<td><img src="image" alt="icon" /></td>
<td><img src="image" alt="icon" /></td>
<td>√</td>
<td><img src="image" alt="icon" /></td>
<td>Company</td>
</tr>
<tr>
<td>Expiry date: 15 Jun 2036</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents</td>
<td>WO2020146788</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="image" alt="icon" /></td>
<td><img src="image" alt="icon" /></td>
<td>√</td>
<td><img src="image" alt="icon" /></td>
<td>Company</td>
</tr>
<tr>
<td>Expiry date: 10 Jan 2040</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiviral compositions that transform short-acting therapeutic agents into long-acting injectable forms that lasts for many weeks per administration</td>
<td>WO2021142150</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="image" alt="icon" /></td>
<td><img src="image" alt="icon" /></td>
<td>√</td>
<td><img src="image" alt="icon" /></td>
<td>Company</td>
</tr>
<tr>
<td>Expiry date: 7 Jan 2041</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------</td>
<td>-----------------------</td>
<td>--------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>---------------</td>
<td>------------------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Drug Combination Nanoparticles for multiple drugs extended release</td>
<td>WO2016205384</td>
<td>Long-acting platform</td>
<td>The University Of Washington</td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 15 Jun 2036</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents</td>
<td>WO2020146788</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 10 Jan 2040</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiviral compositions that transform short-acting therapeutic agents into long-acting injectable forms that lasts for many weeks per administration</td>
<td>WO2021142150</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td><img src="open.png" alt="open" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 7 Jan 2041</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents, WO2020146788, Long-acting platform, University of Washington, (10 Jan 2040)

Source: Company

<table>
<thead>
<tr>
<th>Patent status</th>
<th>Low, low-middle and upper-middle countries</th>
<th>High income countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Filed</td>
<td>China, Brazil, India, Nigeria</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
### Technology patent families

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Combination Nanoparticles for multiple drugs extended release</td>
<td>WO2016205384</td>
<td>Long-acting platform</td>
<td>The University Of Washington</td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 15 Jun 2036</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents</td>
<td>WO2020146788</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 10 Jan 2040</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiviral compositions that transform short-acting therapeutic agents into long-acting injectable forms that lasts for many weeks per administration</td>
<td>WO2021142150</td>
<td>Long-acting platform</td>
<td>University of Washington</td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td><img src="image_url" alt="View" /></td>
<td>Company</td>
</tr>
<tr>
<td><strong>Expiry date:</strong> 7 Jan 2041</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# MPP/Uni Washington licence on Drug Combination Nanoparticles (DcNP) - HIV prevention/treatment

<table>
<thead>
<tr>
<th>Type:</th>
<th>MPP Licence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licensor:</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Jurisdictions:</td>
<td>Afghanistan; Algeria; American Samoa; Angola; Argentina; Armenia; Azerbaijan; Bangladesh; Belarus; Belize; Benin; Bhutan; Bolivia (Plurinational State of); Bosnia and Herzegovina; Botswana; Brazil; Bulgaria; Burkina Faso; Burundi; Cabo Verde; Cambodia; Cameroon; Central African Republic; Chad; China; Colombia; Comoros; Congo; Congo, Democratic Republic of the; Costa Rica; Côte d'Ivoire; Cuba; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt; El Salvador; Equatorial Guinea; Eritrea; Eswatini; Ethiopia; Fiji; Gabon; Gambia (the); Georgia; Ghana; Grenada; Guatemala; Guinea; Guinea-Bissau; Guyana; Haiti; Honduras; India; Indonesia; Iran (Islamic Republic of); Iraq; Jamaica; Jordan; Kazakhstan; Kenya; Kiribati; Korea (Democratic People's Republic of); Kosovo; Kyrgyzstan; Lao People's Democratic Republic (the); Lebanon; Lesotho; Liberia; Libya; Madagascar; Malawi; Malaysia; Maldives; Mali; Marshall Islands; Mauritania; Mexico; Micronesia (Federated States of); Moldova; Republic of; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nepal; Nicaragua; Niger; Nigeria; North Macedonia; Pakistan; Papua New Guinea; Paraguay; Peru; Philippines; Russian Federation; Rwanda; Saint Lucia; Saint Vincent and the Grenadines; Samoa; Sao Tome and Principe; Senegal; Serbia; Sierra Leone; Solomon Islands; Somalia; South Africa; South Sudan; Sri Lanka; State of Palestine; Sudan; Suriname; Syrian Arab Republic; Tajikistan; Tanzania; United Republic of; Thailand; Timor-Leste; Togo; Tonga; Tunisia; Türkei; Turkmenistan; Tuvalu; Uganda; Ukraine; Uzbekistan; Vanuatu; Venezuela (Bolivarian Republic of); Viet Nam; Yemen; Zambia; Zimbabwe</td>
</tr>
</tbody>
</table>

---
LAPaL Landscape

Clinical Trials Regulatory Status

Indication: HIV
Drug Name: Cabotegravir
Use Case: PrEP
Display Timeline By: Trial Phase

Clinical Trial Timeline:

Proportion of Trial Eligibility per Cohort:

Clinical Trial Summary Table:

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Trial Name</th>
<th>Trial ID</th>
<th>Trial Phase</th>
<th>Enrollment</th>
<th>Age Eligibility</th>
<th>Cohort</th>
<th>Current Status</th>
<th>Use Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabotegravir</td>
<td>ECLAIR</td>
<td>NCT02076178</td>
<td>Phase II</td>
<td>127</td>
<td>18-65</td>
<td>Adults, Older Adults</td>
<td>Completed</td>
<td>PrEP</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>HPTN 077</td>
<td>NCT02178800</td>
<td>Phase II</td>
<td>199</td>
<td>18-65</td>
<td>Adults, Older Adults</td>
<td>Completed</td>
<td>PrEP</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>HPTN 083</td>
<td>NCT02720094</td>
<td>Phase II/III</td>
<td>4570</td>
<td>18+</td>
<td>Adults, Older Adults</td>
<td>Active Not Recruiting</td>
<td>PrEP</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>HPTN 084</td>
<td>NCT03164564</td>
<td>Phase III</td>
<td>3224</td>
<td>18-45</td>
<td>Adults</td>
<td>Active Not Recruiting</td>
<td>PrEP</td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>EBONI</td>
<td>NCT05514509</td>
<td>Marketed</td>
<td>250</td>
<td>18+</td>
<td>Adults, Older Adults</td>
<td>Recruiting</td>
<td>PrEP</td>
</tr>
</tbody>
</table>

Showing 1 to 5 of 10 entries
THE LONG-ACTING THERAPEUTICS PATENTS AND LICENCES DATABASE

Lobna Gaayeb
Lgaayeb@mppf.ch

Mark Ryan
M.P.Ryan2@liverpool.ac.uk

Thanks for your attention!
Please reach out to us with questions, proposals for improvements or any comments

www.lapal.ch
Access to Medicines Tracker: Interactive Map (and Table)

Webinar – Spotlight on new PrEP tools and data: From R&D to access
Convened by AVAC, MPP, and Unitaid on 28 November 2023
Presented by Sébastien Morin (Medicines Patent Pool)
**Access to Medicines Tracker: Interactive Map (and Table)**

**Step 1.**
Navigate to the MPP website and select “Progress”/”Access to Medicines Tracker”

**Step 2.**
On the “Access to Medicines Tracker” webpage, scroll down to the “Interactive Map”

**Step 3.**
Explore country-level quarter-by-quarter data on access, filing, approval, and supply of MPP-licensed medicines

More at: https://medicinespatentpool.org
https://medicinespatentpool.org/progress-achievements/access-to-medicines-tracker
https://map.medicinespatentpool.org -> This is the link for direct access to the map in full window mode.
https://map.medicinespatentpool.org/table -> This is the link for direct access to the table in full window mode.

Now, let’s do it!
When do I use each tool?
Cheat Sheet

Where do I go to find information on…?

PrEPWatch

- Technical info on PrEP-applicable LA platforms & compounds (incl. publications & documentation)
- Scaled-up manufacturing information
- Intellectual property information (patents and licences)

LAPaL

- PrEP research studies (incl. implementation studies, modelling studies)
- Information on PrEP product approvals
- Country MoH & WHO PrEP guidelines
- Resources to support PrEP rollout process
- Innovators access commitments

ACCESS TO MEDICINES TRACKER

- Intellectual property access information (patents & licences) for MPP-licensed products (such as CAB-LA)
- Information on filings, approvals, supplies, & suppliers of MPP-licensed products (such as CAB-LA)
- Quarter-by-quarter country-by-country data (with possibility to explore historical data points starting from 2019)
Finding and Using Data

Click here to launch Mentimeter interactive quiz

Find the answers here:
- PrEPWatch
- The Long-Acting Therapeutics Patents and Licenses Database
- Access to Medicines Tracker
Q&A
Thank you!

Further Resources

- PrEPWatch
- PrEPTracker
- Integrated Study Dashboard
- Country Planning for Product Introduction Matrix
- The Long-Acting Therapeutics Patents and Licenses Database
- Access to Medicines Tracker
- MedsPaL
Quiz Questions and Answers
What are the top three countries for PrEP Initiations?

- SOUTH AFRICA
- ZAMBIA
- NIGERIA
Which policy frameworks are available for South Africa?
How many resources does the PrEPWatch library have on demand generation materials for CAB for PrEP aimed at adolescent girls and young women?
In LAPaL, how many long-acting technology platforms could potentially be associated with cabotegravir?

Five platform technologies listed on LAPaL could potentially be coupled with cabotegravir to extend its release.

https://lapal.medicinespatentpool.org/
In how many countries has CAB-LA for PrEP received approval?

44 countries (13 LMICs)

In the absence of a licence, when could generic quality assured versions of lenacapavir enter the market?

Not before 2034 or even 2037 in many LMICs

<table>
<thead>
<tr>
<th>Compound patent families</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent description</td>
</tr>
<tr>
<td>Lenacapavir and analogues (Markush formula) and their use in HIV</td>
</tr>
<tr>
<td>Lenacapavir compound and its use in HIV (oral and parenteral)</td>
</tr>
<tr>
<td>Crystalline forms of Lenacapavir sodium salt</td>
</tr>
<tr>
<td>Representative patent</td>
</tr>
<tr>
<td>WO2014134566</td>
</tr>
<tr>
<td>WO2018035359</td>
</tr>
<tr>
<td>WO2019035904</td>
</tr>
<tr>
<td>Categories</td>
</tr>
<tr>
<td>Compound</td>
</tr>
<tr>
<td>Compound</td>
</tr>
<tr>
<td>Polymorphs</td>
</tr>
<tr>
<td>Patent holder</td>
</tr>
<tr>
<td>Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Gilead Sciences, Inc</td>
</tr>
<tr>
<td>Abstract</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Patent status</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Licence with MPP</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Licence details</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Patent source</td>
</tr>
<tr>
<td>MPP Search, US FDA</td>
</tr>
<tr>
<td>MPP Search, US FDA</td>
</tr>
<tr>
<td>MPP Search, US FDA</td>
</tr>
</tbody>
</table>

**Expiry date:**
- 28 Feb 2034
- 17 Aug 2037
- 16 Aug 2038
Question 4 –part 1

How many clinical trials are ongoing or planned for lenacapavir in the context of PrEP?

4 trials: PURPOSE 1 to 4

**PURPOSE 1**
- Phase 3 study of an investigational drug, lenacapavir, for PrEP and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP in Adolescent Girls and Young Women
- This study will be conducted in South Africa and Uganda

**About PURPOSE 2**
- Phase 3 study of an investigational drug, lenacapavir, for PrEP for Cisgender Men, Transgender Women, Transgender Men, and Gender Non-Binary Individuals Who Have Sex With Partners Assigned Male at Birth
- This study will be conducted in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand

**PURPOSE 3**
- PK, Safety, and Acceptability of LEN for PrEP in Cisgender Women in the United States

**PURPOSE 4**
- PK, Safety, and Acceptability of LEN for PrEP in People Who Inject Drugs

https://lapal.medicinespatentpool.org/landscape
Which of these trials have the earliest primary completion date?

**PURPOSE 1: 2024-09-01**

- **PURPOSE 1**
  - **NCT04994509**
    - Phase: III
    - Status: Active, not recruiting
    - Purpose: Evaluate the efficacy of Lenacapavir (LEN) and Emtricitabine/Tenofovir alafenamide (FTAF) in preventing the risk of human immunodeficiency virus (HIV) infection
    - Use case: PEP

- **PURPOSE 2**
  - **NCT04925752**
    - Phase: III
    - Status: Recruting
    - Purpose: Evaluate the efficacy of Lenacapavir (LEN) in preventing the risk of HIV-1 infection.
    - Use case: PEP

- **PURPOSE 3**
  - **NCT06101329**
    - Phase: II
    - Status: Not yet recruiting
    - Purpose: Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United States.
    - Use case: PEP

- **PURPOSE 4**
  - **NCT06101342**
    - Phase: II
    - Status: Not yet recruiting
    - Purpose: Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs.
    - Use case: PEP

**Trials dates**
- **Anticipated Start Date**: Unspecified
- **Actual Start Date**: 2021-08-30
- **Anticipated Date of Last Follow-up**: Unspecified
- **Estimated Primary Completion Date**: 2024-09-01

[https://lapal.medicinespatentpool.org/compounds/lenacapavir-len#/]
List three countries included in the MPP-licensed territory for generic cabotegravir long-acting injectable, and three countries not included in the licensed territory, but where access may be possible as there are no patents.

- Countries included MPP-licensed territory for generic cabotegravir long-acting injectable can be visualized on this interactive map and are also available from MedsPaL or on the CAB-LA licence page.

- Countries not included in the licensed territory, but where access may be possible as there are no patents can be visualized on this interactive map.

- The full, effective overall territory can be visualized on this interactive map, it is also discussed in an online post by Brook Baker.